RADX Stock Risk & Deep Value Analysis
Radiopharm Theranostics Ltd
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on RADX
We analyzed Radiopharm Theranostics Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RADX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈RADX Performance Overview3yr weekly
Unlock RADX Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
RADX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Radiopharm Theranostics Ltd (RADX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$85.69M
RADX Deep Value Analysis
RADX Red Flags & Warning Signs
Premium- ⚠
Negative or inconclusive clinical trial results for lead candidates
- ⚠
Higher-than-expected cash burn leading to further significant dilution
- ⚠
Delays in clinical trials or regulatory processes
- ⚠
Competitor advancements or market entry of superior therapies
Unlock RADX Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
RADX Financial Health Metrics
Market Cap
$85.69M
RADX Competitive Moat Analysis
PremiumMoat Rating
None
Moat Trend
Expanding
Moat Sources
1 Identified
The potential moat relies entirely on the successful progression of its clinical pipeline, leading to regulatory approval and robust patent protection. Until clinical success is achieved and market exclusivity secured, the moat is not durable. It is currently expanding through ongoing R&D and clinical data generation.
RADX Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
RADX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Financial Results (Estimated late Feb/early Mar 2026)
- •Interim Phase 2 clinical data readout for lead candidate(s) (e.g., PTPµ, PSMA, Granzyme B programs) (Expected Q2-Q3 2026)
- •Presentations at major oncology conferences (e.g., ASCO, SNMMI) (May-June 2026)
Medium-Term (6-18 months)
- •Expansion of clinical programs into additional indications or new territories (6-18 months)
- •Potential strategic partnership or licensing agreement with a larger pharmaceutical company (6-18 months)
- •Initiation of additional Phase 2 or Phase 3 trials for promising candidates (12-18 months)
Long-Term (18+ months)
- •Major clinical trial success leading to regulatory approval filings (18+ months)
- •Establishment as a key player in targeted radiopharmaceutical theranostics (3-5 years)
- •Acquisition by a larger pharmaceutical company seeking to enter/expand in the theranostics space (3-5 years)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
RADX Bull Case: What Could Go Right
- ✓
Positive Phase 2 clinical trial data readouts for any lead candidate
- ✓
Announcement of new strategic partnerships or significant non-dilutive funding
- ✓
Progress in IND filings or expansion into new clinical programs
- ✓
Signs of strong institutional investor interest or capital raises from reputable funds
Bull Case Analysis
See what could go right with Premium
Never miss a move on RADX
Create a free account to set price alerts and get notified on Telegram when RADX hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Radiopharm Theranostics Ltd (RADX)?
As of February 11, 2026, Radiopharm Theranostics Ltd has a DVR Score of 5.8 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Radiopharm Theranostics Ltd?
Radiopharm Theranostics Ltd's market capitalization is approximately $85.7M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Radiopharm Theranostics Ltd use?
RADX is the ticker symbol for Radiopharm Theranostics Ltd. The company trades on the NCM.
What is the risk level for RADX stock?
Our analysis rates Radiopharm Theranostics Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the RADX DVR analysis updated?
Our AI-powered analysis of Radiopharm Theranostics Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 11, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.